Amylin Pharmaceuticals , a San Diego-based biotechnology ... as one of the leaders in diabetes treatment. It is an injectible chemical that appears to be incredibly good at lowering levels of ...

“Our proven GPCR structure-based drug discovery platform enabled us to rapidly advance ACCG-2671 as the lead amylin receptor agonist. We are now developing a series of amylin-based drug ...

Structure Therapeutics Inc. has announced the selection of its lead oral small molecule amylin receptor agonist, ACCG-2671, which shows promising preclinical results including potent target ...

“Our proven GPCR structure-based drug discovery platform enabled us to rapidly advance ACCG-2671 as the lead amylin receptor agonist. We are now developing a series of amylin-based drug candidates ...